Employees Retirement System of Texas trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 44.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the medical research company’s stock after selling 8,000 shares during the period. Employees Retirement System of Texas’ holdings in Bio-Rad Laboratories were worth $2,263,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the business. HighTower Advisors LLC purchased a new position in Bio-Rad Laboratories in the 2nd quarter valued at about $384,000. Ontario Teachers Pension Plan Board purchased a new position in Bio-Rad Laboratories in the 2nd quarter valued at about $271,000. OxFORD Asset Management LLP purchased a new position in Bio-Rad Laboratories in the 2nd quarter valued at about $728,000. Citadel Advisors LLC lifted its holdings in Bio-Rad Laboratories by 744.4% in the 2nd quarter. Citadel Advisors LLC now owns 184,584 shares of the medical research company’s stock valued at $41,773,000 after purchasing an additional 162,725 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in Bio-Rad Laboratories by 11.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 100,888 shares of the medical research company’s stock valued at $22,832,000 after purchasing an additional 10,033 shares in the last quarter. Institutional investors own 62.84% of the company’s stock.
A number of research analysts have issued reports on BIO shares. Jefferies Group LLC restated a “buy” rating and issued a $275.00 target price on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price objective for the company from $220.00 to $195.00 in a research note on Wednesday, June 28th. BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. TheStreet downgraded shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research raised shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Bio-Rad Laboratories has an average rating of “Buy” and a consensus target price of $240.00.
In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the firm’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now directly owns 2,060 shares in the company, valued at approximately $444,774.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 28.29% of the company’s stock.
Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 222.67 on Wednesday. The firm has a market cap of $6.60 billion, a P/E ratio of 440.06 and a beta of 0.91. The stock’s 50 day moving average is $222.12 and its 200-day moving average is $220.81. Bio-Rad Laboratories, Inc. has a 1-year low of $154.89 and a 1-year high of $242.79.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.